Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growth
- Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growth
Generated $0.9 million in positive cash flow from operations; ended quarter with $22.1 million of cash on hand
DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2023. - Eton reported third quarter 2023 product sales and royalty revenue of $7.0 million, representing 118% growth over the prior year period and 8% growth over the second quarter of 2023.
- Product sales and royalty revenue for the third quarter of 2023 were up 8% over the second quarter of 2023.
- As previously announced, Eton will host its third quarter 2023 conference call as follows: